Background {#Sec1}
==========

Although the recurrences that have been observed after complete resection for non-small cell lung cancer (NSCLC) mostly include multiple organs or sites and are treated with systemic anticancer drugs, oligo-recurrence/metastasis is considered a recurrent mode that could be controlled using a definitive local therapy \[[@CR1]--[@CR3]\]. However, selecting the appropriate patients for definitive local therapy remains an intractable issue.

Since the liver is rarely observed as an oligo-recurrence/metastasis site in patients with NSCLC \[[@CR1]\], hepatectomies for liver metastasis from NSCLC have rarely been reported \[[@CR4]\]. We encountered a patient with a rapidly growing solitary liver mass lesion that developed after lung resection for NSCLC and treated the patient using a hepatectomy.

Case presentation {#Sec2}
=================

A 74-year-old man had undergone left lower lobectomy for NSCLC (Fig. [1a](#Fig1){ref-type="fig"}). The tumor was pathologically diagnosed as squamous cell carcinoma of the lung (1.9 cm in size) without lymph node metastasis (TNM classification 7th edition, pT1aN0M0 and stage IB) (Fig. [1b](#Fig1){ref-type="fig"}). He was followed up periodically, and a computed tomography (CT) scan that was taken 1 year after the operation revealed an 8.3 cm, irregularly shaped mass lesion in segment five of the liver (Fig. [1c](#Fig1){ref-type="fig"}). Retrospectively, CT performed 6 months prior showed a 3.1 × 2.9 cm low-density lesion at the identical site (Fig. [1d](#Fig1){ref-type="fig"}). Since 18-fluoro-2-deoxyglucose (^18^F-FDG) positron emission tomography and enhanced brain magnetic resonance imaging (MRI) ruled out any metastatic lesions other than the one in the liver, the patient was referred to a gastroenterological surgeon. Liver MRI demonstrated a well-defined mass, which was hypointense relative to the liver parenchyma on T1-weighted images (Fig. [2a](#Fig2){ref-type="fig"}) and hyperintense on T2-weighted images (Fig. [2b](#Fig2){ref-type="fig"}). The hepatic mass exhibited clear hypointensity in the late dynamic and hepatobiliary phases on ethoxybenzyl diethylenetriaminepentaacetic acid-MRI (Fig. [2c](#Fig2){ref-type="fig"}). Moreover, MRI showed that the mass had increased to 9.6 cm in diameter within a 1-month interval. Although serum levels of carcinoembryonic antigen (CEA; cut-off value, 3.4 ng/ml) and cytokeratin 19 fragment (CYFRA; cut-off value, 3.5 ng/ml) were both within the normal range at the time of lung resection, both CEA and CYFRA levels increased to 11.0 ng/ml and 23.0 ng/ml, respectively, along with enlargement of the hepatic mass (CEA and CYFRA levels at each time point are indicated in Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}).Fig. 1**a** Chest computed tomography (CT) shows 1.8-cm nodule in the left lower lobe of the lung. **b** The pathological image shows squamous cell carcinoma of the lung (hematoxylin-eosin stain). **c** The abdominal CT taken 12 months after lung resection shows an 8.3-cm mass in the right liver. **d** CT taken 6 months after lung resection shows a 3.1-cm low-density lesion in the liver. Insets in **a**, **c**, and **d** show serum levels of tumor markers at the time (upper: carcinoembryonic antigen \[CEA\]; lower: cytokeratin 19 fragment \[CYFRA\])Fig. 2Magnetic resonance imaging demonstrates a large mass with hypointensity on T1-weighted images (**a**) and hyperintensity on T2-weighted images (**b**). The tumor exhibits clear hypointensity in the late dynamic and hepatobiliary phases (**c**). Inset in **c** shows serum levels of tumor markers at the time (upper: carcinoembryonic antigen \[CEA\]; lower: cytokeratin 19 fragment \[CYFRA\])

Since his general condition was good and his major organ functions were tolerable to general anesthesia, the patient underwent right hepatectomy 14 months after the lung resection at the primary site. Intraoperatively, a huge mass was detected in the right liver, but no other metastatic sites were identified. The postoperative course was uneventful, and the patient was discharged on postoperative day 10.

The macroscopic examination of the cut specimen showed an irregular, grayish mass that measured 10 × 8 × 5.5 cm, with massive central necrosis (Fig. [3a](#Fig3){ref-type="fig"}). The pathologic examination confirmed metastatic squamous cell carcinoma of the lung (Fig. [3b](#Fig3){ref-type="fig"}). He did not receive adjuvant chemotherapy and was free from recurrence 41 months after the hepatectomy.Fig. 3**a** A macroscopic image of the cut specimen shows an irregular, grayish mass measuring 10.0 cm with massive central necrosis. **b** The microscopic image of the liver mass shows squamous cell carcinoma

Discussion {#Sec3}
==========

Here, we performed a right hepatectomy for a rapidly growing giant liver metastasis from NSCLC, and the patient did not present recurrence 41 months after the hepatectomy and 54 months after the lung resection. Although the liver is not a common recurrence site \[[@CR3]\], and reported cases of hepatectomies for liver metastases from NSCLC are rare \[[@CR4]\], we recommended surgical resection to this patient. Since the tumor showed substantial growth after we overlooked the liver lesion 6 months before the initial recognition and the new metastatic lesion did not emerge during the 6-month interval, we considered that the liver metastasis could be an oligo-metastasis. Retrospectively, we verified whether our presumption based on an unintentional 6-month observation was supported by the tumor doubling time (TDT) \[[@CR5]\]. In this case, the TDT ranged from 38 to 50 days (Fig. [4](#Fig4){ref-type="fig"}). If the patient had other clinically unrecognizable metastatic lesions that were 2 mm in diameter and could grow to a recognizable 1 cm diameter, this increase would take 116 days, since the TDT is 50 days. Although 6 months is longer than this 116-day interval, we can assume that a single metastatic cell from this patient would require 30 times the TDT (30 × 50 = 1500 days) bio-mathematically \[[@CR6]\] to become a nodule with a diameter of 1 cm. Thus, our presumption that this case truly involves oligo-metastasis is not fully supported by the TDT model. To select appropriate patients with oligo-recurrences/metastases for definitive local therapy, other clinical indicators, such as circulating tumor cells, should be developed \[[@CR7]\].Fig. 4Tumor doubling time (TDT) in the present case between each time point. The indicated formula was described by Hasegawa et al. \[[@CR5]\]

We reviewed hepatectomy cases from the literature available in English and Japanese for reports of metachronous liver metastases from NSCLC, excluding patients who were diagnosed with liver metastasis concurrently with lung cancer, and found 21 cases, including the present one (Table [1](#Tab1){ref-type="table"}) \[[@CR8]--[@CR17]\]. Among these patients, there is a case who is not truly oligo-recurrence because of multiple abdominal lymph node metastases \[[@CR8]\]. Moreover, Nagashima et al. \[[@CR17]\] mentioned that they did not report two other patients who underwent hepatectomies and did not survive. Although it is impossible to rule out selection and publishing biases in our review of reported cases, the median survival time of all cases after hepatectomy is 24.3 months, and the median interval between initial lung surgery and hepatectomy is 11 months (mean 15 months, range 1.6--48 months). The interval is not significantly different between post-hepatectomy survival and mortality cases (mean 16.8 and 11.4 months, Mann-Whitney *U* test: *p* = 0.40). Squamous cell carcinoma was the dominant histologic type, and this finding is consistent with Hishida et al.'s observation \[[@CR1]\], which showed that oligo-recurrence was non-adenocarcinoma histology dominant. On survival analyses, cases of pathological stage I lung cancer showed better post-hepatectomy prognosis than those of pathological stage II or more (2-year survival rate 87.5% and 50.0%, respectively). Moreover, cases with squamous cell carcinoma showed better post-hepatectomy prognosis than those with non-squamous histologies (2-year survival rate 87.5% and 55.6%, respectively). Tumor angiogenesis varies between histologic types \[[@CR18]\], and this might affect the recurrent mode and prognosis after definitive local therapy for recurrence.Table 1Reported cases of hepatectomy for metachronous liver metastases from non-small cell lung cancerNo.AuthorAgeSexPrimary lesionTime interval (months)Liver metastasesManagementStageHistological typeAdjuvant therapyLocationSize (cm)NumberHepatectomy procedureTreatment for recurrencesOutcome (months)1Di Carlo69FLNAAD--48S751P--Alive (36)2Takagi46MLNAPleo--10S6101SCTDead (12)3Nagashima71ML*IB*AD--6S5/S62.5/0.42P--Alive(62)4Nikkumi60ML*IB*SQRT12S771PSurgAlive (73)5Kim55MPn\**IA*SQ--7caudateNA1S--Alive (60)6Ercolani52MLNAADCT24S651S--Dead(36)7Ercolani60FLNAADCT18NA61L--Alive (NA)8Ileana56ML\*IIIALCNEC--24NANA3LCTAlive(21)9Ileana70FCCRTIIIBAD--9NA31NACTDead (5.5)10Ueda77ML*IIA*LACT, RT8S851S--Alive (6)11Ueda65FL*IIIA*ADCT, RT20S721S--Dead (20)12Higaki77MP*IIB*SQ--10S211SRT, BI, CTAlive(33)13Watanabe71ML*IA*AD--11S63.51PEGFRTKIAlive (6)14IshigeNAMSurg*IIIA*SQ--1.6NA4.51SRTDead(15.2)15IshigeNAMSurg*IB*SQ--15NA44PCTAlive(23.4)16IshigeNAMSurg*IIIA*SQCT8NA41SCTDead(24.5)17IshigeNAMSurg*IA*SQ--7NA2.33SNAAlive(30.2)18IshigeNAMSurg*IB*SQCT13NA31PCTAlive(26.2)19IshigeNAFSurg*IB*AD--42NA1.94P--Alive(24)20IshigeNAMSurg*IB*LA--7.4NA7.51S--Dead(16.5)21Present case74ML*IB*SQ--14S59.61L--Alive (41)*NA* not available, *AD* adenocarcinoma, *SQ* squamous cell carcinoma, *LA* large cell carcinoma, *LCNEC* large cell neuroendocrine carcinoma, *Pleo* pleomorphic carcinoma, *CT* chemotherapy, *RT* radiotherapy, *CCRT* concurrent chemoradiotherapy, *time interval* the interval of time between primary lesion treatment and hepatectomy, *P* partial resection, *S* segmentectomy or sectionectomy, *Surg* surgery, *L* lobectomy, *Pn* pneumonectomy, *BI* bronchoscopic intervention, *EGFRTKI* epidermal growth factor receptor tyrosine kinase inhibitorItalic font indicates the pathological stage\*Induction therapy was administered

Conclusion {#Sec4}
==========

We report on a patient who underwent hepatectomy for liver metastasis from NSCLC and remained recurrence free at 41 months after liver surgery. Although we do not have a reliable clinical indicator for selecting oligo-recurrent cases, hepatectomy provides an option for patients with solitary liver metastasis from NSCLC. Based on our review of reported cases, patients with pathological stage I NSCLC and squamous cell carcinoma who undergo hepatectomies demonstrate better post-hepatectomy prognoses.
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